Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
This cohort study of more than 1.6 million patients with type 2 diabetes (T2D) who had no prior diagnosis of 13 OACs found that patients with T2D treated with GLP-1RAs vs insulin had a significant risk reduction in 10 of 13 OACs, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer as well as meningioma and multiple myeloma. No decrease in cancer risk was associated with GLP-1RAs compared with metformin.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833
The benefits of GLP-1 drugs beyond obesity
https://www.science.org/doi/full/10.1126/science.adn4128
Exciting advancements are happening in the world of GLP-1 medications! After nearly 20 years of use for Type 2 Diabetes the future looks even brighter. The next generation of GLP-1 therapies promises to be even more powerful, with potential benefits extending beyond cardiometabolic disorders. Stay tuned as we continue to explore these groundbreaking options for improved health and wellness!
Learn about these exciting advancements during your consultation with our Board-Certified Nurse Practitioners
Copyright © 2025-Fleming Adult Health NP, PLLC- All Rights Reserved.